corresp
|
|
|
|
|
Aastrom Biosciences |
|
|
Dominos Farms, Lobby K |
|
|
24 Frank Lloyd Wright Drive |
|
|
Ann Arbor, MI 48105 |
|
|
T 734 418-4400 F 734 6650485 |
|
www.aastrom.com |
June 7, 2011
VIA EDGAR AND FEDERAL EXPRESS
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jim B. Rosenberg
|
|
|
Re: |
|
Aastrom Biosciences, Inc.
Form 10-K for the Year Ended June 30, 2010
Form 10-K/A for the Year Ended June 30, 2010
File No. 000-22025 |
Ladies and Gentlemen:
This letter is being supplementally furnished by Aastrom Biosciences, Inc. (the Company) in
connection with the comments of the staff of the Division of Corporation Finance (the Staff) of
the Securities and Exchange Commission (the Commission) raised in your letters dated January 28,
2011 and March 29, 2011 regarding the Companys Form 10-K for the fiscal year ended June 30, 2010
filed on September 7, 2010 and Form 10-K/A for the fiscal year ended June 30, 2010 filed on
February 24, 2011 (collectively, the Comment Letters). As a follow-up to discussions related to
the Comment Letters between the Company and certain of its representatives and members of the Staff
on June 2, 2011 and June 3, 2011 during which the Staff requested that the Company confirm in
writing its accounting for certain of its outstanding warrants to purchase shares of common stock,
the Company is providing the following information.
The Company respectfully advises the Staff that it believes that the Companys application of
liability accounting for certain of its warrants is the appropriate treatment for such warrants in
accordance with Accounting Standards Codification 815, Derivatives and Hedging (ASC 815), which
requires that warrant instruments that could potentially require net cash settlement outside the
control of the Company, should be
initially classified as derivative liabilities at their estimated fair values, regardless of the
likelihood that such instruments will ever be settled in cash. In reaching this conclusion, while
not directly on point, the Company also considered the guidance presented at the 2006 AICPA
National Conference on Current SEC and PCAOB Developments made by Stephanie L. Hunsaker regarding
accounting for warrants issued as part of a registered offering (the Hunsaker Speech).
U.S. Securities and Exchange Commission
June 7, 2011
Page 2
The warrants that are the focus of the discussion include (collectively, the Warrants) warrants
to purchase an aggregate of 740,131 shares of the Companys common stock, issued in October 2007 at
an exercise price of $12.72 per share.
These Warrants generally provide that, in the event the related registration statement is not
available for the issuance of the Warrant shares, the holder may exercise the Warrant on a cashless
basis (i.e., applying a portion of the Warrant shares to the payment of the exercise price).
In determining the appropriate accounting treatment for these Warrants, the Company analyzed the
terms of the Warrants and the circumstances related to the issuances of such Warrants. As a result
of such analysis, the Company determined that the holder of the Warrant(s) has an expectation that
registered shares of common stock of the Company will be issued upon exercise of the Warrant
because (1) the Warrants were issued pursuant to a registered offering of securities of the
Company, and (2) there may be a contractual obligation of the Company to deliver registered shares
upon the exercise of the Warrant. Specifically, the Company advises the Staff that Section 8
(Reservation of Stock; Registration) of the Warrant states that the Company will register the
shares at its sole expense...in order to permit the free tradability of the Warrant shares without
restriction. Furthermore, pursuant to Section 3.3 of Annex II of the purchase agreements between
the Company and the purchaser of securities in the October 2007 registered offering, the Company
agreed to use its commercially reasonable best efforts to maintain the effectiveness of the
Registration Statement until the expiration of the Warrants. Lastly, there is no provision in the
Warrants that precludes the holder of the Warrant from demanding net cash settlement of such
Warrant in the event that an effective registration statement relating to the Warrants is not
available.
As a result of the foregoing, the Company respectfully advises the Staff that it believes that the
holder of such Warrant has a choice as to the manner of settlement of such Warrant
when an effective registration statement is not available for the exercise of such Warrant. The
holder may elect to exercise pursuant to the net share settlement provisions such that
unregistered shares of common stock are issued upon exercise thereof; however, there is no
requirement that the holder do so, rather it is permissive. Alternatively, if the holder of the
Warrant does not elect to exercise pursuant to the net share settlement provisions in those
circumstances, the holder may be able to allege a breach of contract claim against the Company for
failure to deliver registered shares of its common stock upon exercise. Such an alleged claim may
lead to an obligation outside of the Companys control to settle the warrants in cash. The
Company also concluded that potential cash settlement was an economically equivalent alternative
given that the holders cost to litigate would not be a significant enough penalty to make it an
uneconomic settlement. Accordingly, in light of the potential foregoing outcome and the guidance
in ASC 815 and the Hunsaker Speech, the Company believes that the Warrants are appropriately
classified as liabilities of the Company.
* * *
U.S. Securities and Exchange Commission
June 7, 2011
Page 3
If you should have any questions concerning the enclosed matters, please contact the undersigned at
(734) 418-4420.
Very truly yours,
/s/ Scott C. Durbin
Scott C. Durbin, Chief Financial Officer
|
|
|
cc: |
|
Timothy Mayleben, Aastrom Biosciences, Inc.
Mitchell S. Bloom, Esq., Goodwin Procter LLP
Danielle Lauzon, Esq., Goodwin Procter LLP
Jacqueline Mercier, Esq., Goodwin Procter LLP
Jeff Riedler, U.S. Securities and Exchange Commission
Todd Hardiman, U.S. Securities and Exchange Commission
Mark Brunhofer, U.S. Securities and Exchange Commission
Kei Nakada, U.S. Securities and Exchange Commission
Scot Foley, U.S. Securities and Exchange Commission
John Berglund, PricewaterhouseCoopers, LLP |